Radioiodine treatment of pediatric Graves disease: a multicenter review

Trout, Andrew T.; Khalatbari, Hedieh; Shogbesan, Gbenga; Mirza, Sobia; Sharp, Susan E.; Alazraki, Adina; Parisi, Marguerite T.

doi:10.1007/s00247-022-05415-6

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are various methods for determining the appropriate dosage. Some physicians opt for a fixed dose, while others base the calculation on the size of the thyroid gland [8,35]. Although it has not been conclusively shown which method is superior, recent guidelines recommend personalized RAI dosing that takes into account the size of the thyroid gland as estimated by ultrasound [9].…”

Section: Radioactive Iodine Therapymentioning

confidence: 99%

Updates in the Management of Graves Disease in Children

Lee

2023

Ewha Med J

View full text Add to dashboard Cite

Graves disease (GD) is the primary cause of hyperthyroidism in children. The standard management options-namely, antithyroid drugs (ATD), radioactive iodine, and surgery-have not changed for many years. Although ATD therapy is often the first-line treatment for pediatric patients, the low likelihood of spontaneous remission means that most children will require a more permanent solution. Recent clinical trials and systematic reviews have shed light on the long-term outcomes of ATD therapy, radioactive iodine, and surgical interventions in managing pediatric GD. Additionally, novel therapies aimed at B-cells or the thyroid-stimulating hormone receptor, both implicated in the pathogenesis of GD, are under investigation. However, their definitive role in treating childhood GD has yet to be established. This review will cover the latest developments in the treatment of childhood GD, including information on emerging targeted therapies.

show abstract

Section: Radioactive Iodine Therapymentioning

confidence: 99%